DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Park K.
Updated safety and efficacy results from phase I/II study of HM61713 in patients (pts) with EGFR mutation positive non-small cell lung cancer (NSCLC) who failed previous EGFR-tyrosine kinase inhibitor (TKI).
J Clin Oncol 2015; (suppl): abstr 8084
33
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.